Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00582_DB01254_nanopub.RANFocmID_7tm7TaMqREVHNDGpMY7XClqixf1Z5giQ6Do#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00582_DB01254 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00582_DB01254 label "DDI between Voriconazole and Dasatinib - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00582_DB01254]" assertion.
- drugbank_resource:DB00582_DB01254 identifier "drugbank_resource:DB00582_DB01254" assertion.
- drugbank_resource:DB00582_DB01254 title "DDI between Voriconazole and Dasatinib - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00582 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01254 assertion.
- drugbank:DB01254 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01254 assertion.